Safety and Immunogenicity of NVX-CoV2705

NCT07079670 | Active Not Recruiting Phase 3 DMC FDA Drug

• 2 other identifiers: 2019nCoV-318VBV23344
• Study Type: interventional
• Target: 676
• Locations: 1 country
• Sites: 10

Brief Summary

This study is a Phase 3 trial designed to check the safety and immune response to a new Omicron JN.1 COVID-19 vaccine. Study researchers will give a single dose of this vaccine, called NVX-CoV2705, to approximately 120 participants. This includes adults aged 65 and older, and individuals aged 12 to 64 who have existing health conditions that put them at high risk for severe COVID-19. All participants must have received a previous COVID-19 vaccine at least 90 days before joining this study. Study researchers will be closely monitoring participants for their immune response for 28 days and collecting safety data for 180 days after vaccination.

Conditions

COVID-19; SARS-CoV-2 Infection

Keywords

COVID-19

Outcome Measures

Primary Outcomes (1)

• Pseudovirus neutralization (ID50) of Omicron JN.1 subvariant vaccine expressed as GMFR

  Pseudovirus neutralization (ID50) GMFR for the Omicron JN.1 subvariant at Day 28 following study vaccination.

  Day 28

Secondary Outcomes (5)

• Pseudovirus neutralization (ID50) of Omicron JN.1 subvariant vaccine expressed as GMT

  Day 28

• Pseudovirus neutralization (ID50) of Omicron JN.1 subvariant vaccine expressed as SRR

  Day 28

• Number of Participants Reported Solicited Local and Systemic Adverse Events (AEs)

  Day 28

• Number of Participants Reported any unsolicited AEs and MAAEs

  Day 28

• Number of Participants Reported MAAEs Attributed to Study Vaccine, Adverse Events of Special Interest (AESIs), and Serious Adverse Events (SAEs)

  Day 180

Study Arms (1)

NVX-CoV2705

EXPERIMENTAL

NVX-CoV2705 vaccine in a 0.5 mL injection volume at an antigenic dose of 5 µg with 50 µg Matrix-M adjuvant.

Biological: NVX-CoV2705

Interventions

NVX-CoV2705 BIOLOGICAL

Intramuscular (deltoid) injection at an antigenic dose of 5 µg with 50 µg Matrix-M adjuvant.

Also known as: Omicron JN.1 Subvariant SARS-CoV-2 rS Vaccine Adjuvanted with Matrix-M

NVX-CoV2705

Eligibility Criteria

• Age: 12 Years - 90 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• To be included in this study, each individual must satisfy all the following criteria:
• Participants ≥ 65 years of age and participants 12 through 64 years who have at least one underlying condition that puts them at high risk of severe outcomes from COVID-19 at time of study vaccination. In each instance, the investigator's judgment may be exercised and other eligibility criteria must be respected.
• Previously vaccinated with a COVID-19 vaccine with the last dose administered ≥ 90 days prior to study vaccination (written or verbal confirmation by participant).
• Participant and parent(s)/caregiver(s) or legally acceptable representative willing and able to give informed consent and assent prior to study enrollment and to comply with study procedures.
• Female participants of childbearing potential (defined as any participant who has experienced menarche and who is NOT surgically sterile \[ie, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy\] or postmenopausal \[defined as amenorrhea ≥ 12 consecutive months\]) must agree to be heterosexually inactive from at least 28 days prior to enrollment and through the end of the study OR agree to consistently use a medically acceptable method of contraception listed below from ≥ 28 days prior to enrollment and through the end of the study.
• Condoms (male or female) with spermicide (if acceptable in country)
• Diaphragm with spermicide
• Cervical cap with spermicide
• Intrauterine device
• Oral or patch contraceptives
• Norplant®, Depo-Provera®, or other in country regulatory approved contraceptive method that is designed to protect against pregnancy
• Abstinence, as a form of contraception, is acceptable if in line with the participant's lifestyle NOTE: Periodic abstinence (eg, calendar, ovulation, sympto-thermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
• Is medically stable, as determined by the investigator (based on review of health status, vital signs \[to include body temperature\], medical history, and physical examination. Vital signs must be within medically acceptable ranges prior to study vaccination. If the individual has a diagnosis of hypertension, it must be stable and controlled with necessary medication.
• Agrees not to participate in any research involving receipt of investigational products (drug/biologic/device), including other SARS-CoV-2 prevention or treatment trials, for the duration of the study.

You may not qualify if:

• If an individual meets any of the following criteria, he or she is ineligible for this study:
• Current participation in research involving receipt of investigational products (drug/biologic/device).
• Received any other vaccine (except for a licensed seasonal influenza vaccine or rabies vaccine \[if medically indicated\]) within 28 days prior to study vaccination. For the influenza vaccine, a participant is eligible as long as the vaccine was administered ≥ 14 days prior to study vaccination.
• Any known history of allergies to products contained in the investigational product in the participant's lifetime.
• Any known history of anaphylaxis to any prior vaccine in the participant's lifetime.
• Known history of myocarditis or pericarditis in the participant's lifetime.
• Suspected or known history of alcohol abuse or drug addiction within 2 years prior to study vaccination that, in the opinion of the investigator, might interfere with protocol compliance.
• Autoimmune or immunodeficiency disease/condition (iatrogenic or congenital) that requires the use of immune modulators.
• NOTE: Stable endocrine disorders (eg, thyroiditis, pancreatitis), including stable diabetes mellitus with no history of diabetic ketoacidosis, are NOT excluded.
• Chronic administration (defined as \> 14 continuous days) of immunosuppressant, systemic glucocorticoids, or other immune-modifying drugs within 90 days prior to study vaccination (Day 0).
• NOTE: An immunosuppressant dose of glucocorticoid is defined as a systemic dose ≥ 10 mg of prednisone per day or equivalent. The use of topical, inhaled or intranasal glucocorticoids is permitted. Topical tacrolimus and ocular cyclosporin are permitted.
• Received any prohibited medication (see Section 7.3), immunoglobulin, blood-derived products, or immunosuppressant drugs within 90 days prior to study vaccination (Day 0).
• Active cancer (malignancy) on chemotherapy within 3 years prior to study vaccination (with the exception of adequately treated non-melanomatous skin carcinoma or lentigo maligna and uterine cervical carcinoma in situ without evidence of disease, at the discretion of the investigator).
• Participants who are breastfeeding, pregnant, or who plan to become pregnant prior to the end of study.
• Any other condition that, in the opinion of the investigator, would pose a health risk to the participant if enrolled or could interfere with evaluation of the study vaccine or interpretation of study results (including neurologic or psychiatric conditions likely to impair the quality of safety reporting).

Sponsors & Collaborators

• Sanofi: lead
• Novavax: collaborator

Study Sites (10)

Investigational Site Number US404

Phoenix, Arizona, 85044, United States

Location

Investigational Site Number US395

Melrose Park, Illinois, 60160, United States

Location

Investigational Site Number US406

Lenexa, Kansas, 66219, United States

Location

Investigational Site Number US294

Lafayette, Louisiana, 70508, United States

Location

Investigational Site Number US407

Southfield, Michigan, 48076-5412, United States

Location

Investigational Site Number US326

Omaha, Nebraska, 68134, United States

Location

Investigational Site Number US381

Cincinnati, Ohio, 45246-2316, United States

Location

Investigational Site Number US047

Austin, Texas, 78705-3298, United States

Location

Investigational Site Number US073

Tomball, Texas, 77375, United States

Location

Investigational Site Number US391

Pleasant View, Utah, 84404-4791, United States

Location

MeSH Terms

Conditions

COVID-19

Interventions

Matrix-M

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NA
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 14, 2025
• First Posted: July 23, 2025
• Study Start: October 9, 2025
• Primary Completion: April 16, 2026
• Study Completion (Estimated): June 16, 2026
• Last Updated: February 13, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will share

Locations

US (10)